FORM PTO-1449

INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.
0609.4810002/TJS/FRC

APPLICATION NO.
10/643,226

APPLICANT
Bush et al.

FILING DATE
August 19, 2003

APPLICATION NO.
10/643,226

APPLICANT
Bush et al.

U.S. PATENT DOCUMENTS								
EXAMINER INITIAL		DOCU	MENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA							
	AB							
	AC							
	AD							
	AE							
	AP							
	AG							
	AH	<u> </u>						
	AI							
	AJ	1			,			
	AK	<u> </u>		<u> </u>		<u> </u>		
	·	,		FOREIGN P.	ATENT DOCUMENTS	-		
EXAMINER INITIAL		DOCU	MENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	l							Yes
	AL	L						No
		1	•	1				Yes
	AM					ļ		No
								Yes
	AN					<u> </u>		No
	Ì				·	1		Yes
	AO	<u> </u>	•	<u> </u>				No
								Yes
	AP	<u> </u>				<u>L.</u>		No
		01	HER (Includin	g Author, Ti	tle, Date, Pertinent Pag	ges, etc	.)	
/AD/	AR	<u>52</u>	Skinner, M., et al., "Observations on the amyloid-degrading activity of serum and its relationship to human neutrophil elastase," Trans. Assoc. Am. Phys. 96:437-443, William J. Dornan (1983).					
	AS	<u>52</u>	Smalheiser, N.R., and Swanson, D.R., "Indomethacin and Alzheimer's disease," Neurology 46:583, Lippincott, Williams & Wilkins (February 1996).					
	AT	<u>52</u>	Smith, C., et al., "The molecular pathology of Albheimer's disease: are we any closer to understanding the neurodegenerative process?" Neuropathol. Appl. Neurobiol. 20:322-338, Blackwell Scientific Publications (1994).					
EXAMINER			/Aditi Dut	V		DATE	CONSIDERED (05/22/2007
			_					

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449

INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO. 0609.4810002/TJS/FRC	APPLICATION NO. 10/643,226	
APPLICANT Bush et al.		
FILING DATE	GROUP 1649	

					FILING DATE August 19, 2003	-1	1649	9		
U.S. PATENT DOCUMENTS										
EXAMINER INITIAL		מסכעו	MENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE		
	AA									
	AB									
	AC									
	AD									
	AE					<u> </u>				
	AF	<u> </u>	, 							
	AG									
	АН	ļ			<u> </u>					
	AI	<u> </u>			•	ļ				
	AJ		·			ļ				
	AK	<u> </u>				<u> </u>	<u></u>			
	· · · · · ·			FOREIGN PA	ATENT DOCUMENTS	1	,	,		
EXAMINER INITIAL		DOCU	MENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION		
								Yes		
	AL							No		
	ļ.,,							Yes		
	AM	├				 		No Yes		
	AN	l						1		
	AN	 		 		 	ļ	No Yes		
	AO]						No		
	AU.	 				 		Yes		
	AP			i		1		No		
/AD/ Sue, YI. et al., "Efficacy of magnesium citrate cathartic in pediatric toxic										
,,,,,,,	AR	<u>67</u>	Sue, YJ. et al., "Efficacy of magnesium citrate cathartic in pediatric toxic ingestion," Annals of Emergency Medicine 24(4): 709-712, American College of Emergency Physicians (1994).							
			Cardelli. M.1	B., et al., '	'Chelation Therapy: Unpr	oved Mo	dality in th	he Treatment		
	AS	<u>67</u>	Cardelli, M.B., et al., "Chelation Therapy: Unproved Modality in the Treatment of Alzheimer-Type Dementia," <i>J. Am. Geriatr. Soc.</i> 33:548-551, American Geriatric Society (1985).							
	Ishii, T., and Bannai, S., "The Synergistic Action of the Copper Chelator Bathocuproine Sulphonate and Cysteine in Enhancing Growth of L1210 Cells In Vitro," J. Cell. Physiol. 125:151-155, Alan R. Liss, Inc. (1985).									
EXAMINER	L	<u> </u>	L			DATE	CONSIDERED			
							,			
			/Auti Dui	<u> </u>			05/22/200			

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.